ECSP21091203A - Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa - Google Patents

Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa

Info

Publication number
ECSP21091203A
ECSP21091203A ECSENADI202191203A ECDI202191203A ECSP21091203A EC SP21091203 A ECSP21091203 A EC SP21091203A EC SENADI202191203 A ECSENADI202191203 A EC SENADI202191203A EC DI202191203 A ECDI202191203 A EC DI202191203A EC SP21091203 A ECSP21091203 A EC SP21091203A
Authority
EC
Ecuador
Prior art keywords
pyrazole compounds
disubstituted pyrazole
ketohexokinase inhibitors
formula
ketohexokinase
Prior art date
Application number
ECSENADI202191203A
Other languages
English (en)
Inventor
David Andrew Coates
Steven Marc Massey
James Lee Toth
Timothy Barrett Durham
Richard Duane Johnston
Douglas Richard Stack
Patrick Gianpietro Spinazze
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21091203A publication Critical patent/ECSP21091203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la Fórmula I: (VER ANEXO) o una sal farmacéuticamente aceptable del mismo y el uso de los compuestos de la Fórmula I para el tratamiento de afecciones metabólicas, tales como la diabetes mellitus tipo 2, la insuficiencia cardíaca, la enfermedad renal diabética y la esteatohepatitis no alcohólica.
ECSENADI202191203A 2019-06-17 2021-12-17 Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa ECSP21091203A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862382P 2019-06-17 2019-06-17
US202062975887P 2020-02-13 2020-02-13

Publications (1)

Publication Number Publication Date
ECSP21091203A true ECSP21091203A (es) 2022-01-31

Family

ID=71950812

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202191203A ECSP21091203A (es) 2019-06-17 2021-12-17 Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa

Country Status (23)

Country Link
US (2) US11124500B2 (es)
EP (1) EP3983404B1 (es)
JP (2) JP6986653B2 (es)
KR (1) KR20220008882A (es)
CN (1) CN114008036B (es)
AU (1) AU2020295979A1 (es)
BR (1) BR112021023153A2 (es)
CA (1) CA3143490C (es)
CL (1) CL2021003342A1 (es)
CO (1) CO2021016870A2 (es)
CR (1) CR20210600A (es)
EC (1) ECSP21091203A (es)
ES (1) ES2961283T3 (es)
IL (1) IL288350A (es)
JO (1) JOP20210329A1 (es)
MA (1) MA56208A (es)
MX (1) MX2021015325A (es)
PE (1) PE20220377A1 (es)
PH (1) PH12021553161A1 (es)
TW (1) TWI750685B (es)
UA (1) UA126847C2 (es)
WO (1) WO2020257171A1 (es)
ZA (1) ZA202109067B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021129817A1 (zh) * 2019-12-25 2021-07-01 南京明德新药研发有限公司 具有果糖激酶(khk)抑制作用的嘧啶类化合物
CN114181198B (zh) * 2020-09-15 2025-07-15 山东轩竹医药科技有限公司 嘧啶衍生物类己酮糖激酶抑制剂及其用途
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
EP4313967B1 (en) 2021-03-29 2025-11-12 Gilead Sciences, Inc. Khk inhibitors
TWI833193B (zh) * 2021-04-01 2024-02-21 南韓商Ｌｇ化學股份有限公司 二唑化合物及含彼的藥學組成物
EP4434982A4 (en) * 2021-12-24 2025-03-12 LG Chem, Ltd. (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
AR132416A1 (es) * 2023-04-12 2025-06-25 Centennial Therapeutics Llc Compuestos de pirimidina disustituidos para la inhibición de la cetohexoquinasa
KR20260022334A (ko) 2023-05-31 2026-02-19 센테니얼 테라퓨틱스, 엘엘씨 케토헥소키나제 억제를 위한 이환식 화합물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111247B1 (ko) * 2009-07-17 2012-06-12 한국과학기술연구원 Ｒｏｓ 카이네이즈 저해활성을 갖는 피라졸 화합물
WO2017075367A1 (en) * 2015-10-28 2017-05-04 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
TN2018000198A1 (en) * 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物

Also Published As

Publication number Publication date
TW202112768A (zh) 2021-04-01
US11124500B2 (en) 2021-09-21
JP7221367B2 (ja) 2023-02-13
US20220017496A1 (en) 2022-01-20
MX2021015325A (es) 2022-01-18
TWI750685B (zh) 2021-12-21
CA3143490C (en) 2024-03-05
EP3983404A1 (en) 2022-04-20
US20200392118A1 (en) 2020-12-17
JOP20210329A1 (ar) 2023-01-30
CR20210600A (es) 2022-01-11
KR20220008882A (ko) 2022-01-21
CL2021003342A1 (es) 2022-09-09
PE20220377A1 (es) 2022-03-16
ES2961283T3 (es) 2024-03-11
CA3143490A1 (en) 2020-12-24
CN114008036A (zh) 2022-02-01
EP3983404B1 (en) 2023-08-09
IL288350A (en) 2022-01-01
WO2020257171A1 (en) 2020-12-24
JP6986653B2 (ja) 2021-12-22
ZA202109067B (en) 2023-06-28
MA56208A (fr) 2022-04-20
CN114008036B (zh) 2025-01-17
JP2022031816A (ja) 2022-02-22
BR112021023153A2 (pt) 2022-01-04
JP2021525793A (ja) 2021-09-27
US11999722B2 (en) 2024-06-04
PH12021553161A1 (en) 2022-08-08
AU2020295979A1 (en) 2021-12-09
CO2021016870A2 (es) 2022-01-17
UA126847C2 (uk) 2023-02-08

Similar Documents

Publication Publication Date Title
ECSP21091203A (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
ECSP21015267A (es) Compuestos de 2,6-diaminopiridina
CO2022017226A2 (es) Antagonistas del receptor de lpa y usos de los mismos
CO2023001407A2 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
BR112014003237A2 (pt) compostos de indazol, composições e métodos de uso
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2019013937A (es) Metodo para preparar compuesto derivado heterociclico, composicion que contiene el mismo compuesto, e hidrato del mismo compuesto.
MX2024005142A (es) Agonistas del receptor 1 de peptidos de la familia de la relaxina (rxfp1).
CL2024001470A1 (es) Inhibidores de aldosterona sintasa para tratar la enfermedad renal crónica
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
MX2019010108A (es) Derivados de azetidina.
CL2025001515A1 (es) Uso de finerenona para tratar la enfermedad renal crónica en la diabetes mellitus tipo i.
EA202192957A1 (ru) Дизамещенные пиразольные соединения в качестве ингибиторов кетогексокиназы
MX2022000729A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021001089A (es) Borato de derivado de azetidina.
AR115865A2 (es) Compuestos terapéuticos
AR105924A1 (es) Compuestos terapéuticos y síntesis
UY30825A1 (es) Ureas n-[3-[4-(4-cianofenil)piperidina-1-carbonil]fenil]-n'-(alquilo sustituido)sustituidas, procedimiento para la preparacion y aplicaciones